<DOC>
	<DOCNO>NCT02449603</DOCNO>
	<brief_summary>This multi-centre , open-label , randomize , parallel trial compare effect Exenatide versus Biphasic insulin Aspart 30 glucose variability inflammatory marker type 2 diabetes mellitus ( T2DM ) patient inadequately control metformin monotherapy .</brief_summary>
	<brief_title>Comparison Exenatide vs. Biphasic Insulin Aspart 30 Glucose Variability Type 2 Diabetes</brief_title>
	<detailed_description>Studies show fluctuation glucose seem deleterious effect sustain hyperglycaemia development diabetic complication . The present randomized control trial design primary aim evaluate glycaemic fluctuation comparison twice-daily Exenatide treatment paradigm ( e.g . insulin Aspart 30 ) .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin degludec , insulin aspart drug combination</mesh_term>
	<mesh_term>Exenatide</mesh_term>
	<mesh_term>Insulin aspart , insulin aspart protamine drug combination 30:70</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Biphasic Insulins</mesh_term>
	<mesh_term>Insulin Aspart</mesh_term>
	<mesh_term>Insulin , Long-Acting</mesh_term>
	<mesh_term>Insulin , Isophane</mesh_term>
	<criteria>Provision inform consent prior study specific procedure . Men woman ( nonpregnant use medically approve birthcontrol method ) age 18 70 year screen . Confirmed type 2 diabetes history least half year . Treatment stable , maximum tolerated dos metformin ( ≧1500mg/d , ≧3 month ) . HbA1c ≥ 7.5 % ≤ 10.0 % screen within 4 week prior screen ( local laboratory ) . Body mass index : 2135 kg/m^2 . Women pregnant , intend become pregnant study period , currently lactate female , woman childbearing potential use highly effective , medically approve birth control method . Diagnosis history : 1 . Type 1 diabetes mellitus , diabetes result pancreatic injury secondary form diabetes , e.g. , acromegaly Cushing 's syndrome . 2 . Acute metabolic diabetic complication ketoacidosis hyperosmolar coma within past 6 month . Previous treatment dipeptide peptidase4 ( DPP4 ) inhibitor glucagonlike peptide1 ( GLP1 ) receptor agonist within past one year . History hypersensitivity reaction ( e.g. , anaphylaxis , angioedema , exfoliative skin condition ) dipeptide peptidase4 inhibitor ( DPP4 ) Acarbose . Treatment antidiabetic medication 7 consecutive day metformin last 3months prior screening . Treatment systemic glucocorticoid ( oral , intravenous ) consecutive 7 day within past 6 month . Triglycerides ( fast ) &gt; 4.5 mmol/L ( &gt; 400 mg/dL ) screening within 4 week prior screen ( local laboratory ) . Patients clinically apparent liver disease characterize either one following : 1 . Alanine transaminase ( ALT ) aspartate aminotransferase ( AST ) &gt; 3x upper limit normal ( ULN ) confirm two consecutive measurement ( local laboratory ) within 4 week prior screen period 2 . Impaired excretory ( e.g . hyperbilirubinemia ) and/or synthetic function , condition decompensated liver disease coagulopathy , hepatic encephalopathy , hypoalbuminemia , ascites bleed oesophageal varix . 3 . Acute viral active autoimmune , alcoholic , type hepatitis . Patients moderate /severe renal impairment endstage renal disease ( estimate Glomerular Filtration Rate ≤ 60 mL/min calculate use abbreviated equation develop Modification Diet Renal Disease ( MDRD ) study modification Chinese population ) screen within 4 week prior screen ( local laboratory ) Congestive heart failure define New York Heart Association ( NYHA ) class III IV . Significant cardiovascular history within past 3 month prior screen define : myocardial infarction , coronary angioplasty bypass graft ( ) , valvular disease repair , unstable angina pectoris , transient ischemic attack , cerebrovascular accident . History chronic pancreatitis idiopathic acute pancreatitis . History gastrointestinal disease include gastroenterostomy , enterectomy , Roemheld Syndrome , severe hernia , intestinal obstruction , intestinal ulcer . History genetic galactose intolerance , Lapp lactase deficiency glucosegalactose malabsorption . History medullary thyroid carcinoma . Diagnosed and/or treat malignancy ( except basal cell skin cancer , situ carcinoma cervix , situ prostate cancer ) within past 5 year . History organ transplant acquire immunodeficiency syndrome ( AIDS ) . History alcohol abuse illegal drug abuse within past 12 month . Potentially unreliable patient judge Investigator unsuitable study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>Chinese population</keyword>
</DOC>